Related Experiment Video
Updated: May 22, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation
Peter B Bitterman1, Vitaly A Polunovsky
1Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Abstract:
Notwithstanding their genetic complexity, different cancers share a core group of perturbed pathways converging upon a few regulatory nodes that link the intracellular-signaling network with the basic metabolic machinery. The clear implication of this view for cancer therapy is that instead of targeting individual genetic alterations one by one, the next generation of cancer therapeutics will target critical hubs in the cancer network. One such hub is the translation-initiation complex eIF4F, which integrates several cancer-related pathways into a self-amplifying signaling system. When hyperactivated by apical oncogenic signals, the eIF4F-driven translational apparatus selectively switches the translational repertoire of a cell toward malignancy. This central integrative role of pathologically activated eIF4F has motivated the development of small-molecule inhibitors to correct its function. A genome-wide, systems-level means to objectively evaluate the pharmacologic response to therapeutics targeting eIF4F remains an unmet challenge.
Insights
Cancer cells hijack key signaling hubs like the translation-initiation complex eIF4F to promote malignancy. Targeting these critical nodes offers a promising therapeutic strategy for next-generation cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling Networks
Background:
- Cancers, despite genetic diversity, share common perturbed pathways converging on regulatory nodes.
- These nodes link intracellular signaling with cellular metabolism, presenting therapeutic targets.
- The translation-initiation complex eIF4F is a critical hub integrating cancer-related pathways.
Purpose of the Study:
- To highlight the role of the eIF4F complex as a central integrator of oncogenic signaling.
- To underscore the potential of targeting eIF4F for cancer therapy.
- To identify the need for genome-wide methods to assess responses to eIF4F inhibitors.
Main Methods:
- The study reviews the role of eIF4F in integrating cancer signaling pathways.
- It discusses the implications of eIF4F hyperactivation in cancer development.
- The need for systems-level evaluation of therapeutic responses is emphasized.
Main Results:
- Hyperactivation of eIF4F by oncogenic signals drives a translational shift towards malignancy.
- The eIF4F complex acts as a central hub, amplifying oncogenic signals.
- Small-molecule inhibitors targeting eIF4F are under development.
Conclusions:
- Targeting critical network hubs like eIF4F is a key strategy for next-generation cancer therapeutics.
- Understanding eIF4F's role provides insights into cancer cell reprogramming.
- Developing objective, genome-wide methods to evaluate drug response is crucial.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation

